Padam Hirachan, MD
Nephrology · Natchez, MSNPI 1528215019
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,650 of the $28,910 with a category attached, or 68.0%. 25 manufacturers reported payments, led by Vifor Pharma, Inc. at 50.6% of the total. Reporting peaked in 2019 at $15,295 and has fallen 95.4% since, to $698 in 2025. Among nephrology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $165.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$15K
- Akebia Therapeutics Inc$8K
- Baxter Healthcare$3K
- AstraZeneca$485
- Otsuka America Pharmaceutical, Inc.$361
- Bayer$256
- plus $1K from 19 others
What the payments were for
- Consulting fees$3,12011%
- Speaking & faculty fees$19,65068%
- Travel & lodging$1,8136%
- Food & beverage$3,92014%
- Education$4081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 42 | $14,617 |
| Akebia Therapeutics Inc | 28 | $8,393 |
| Baxter Healthcare | 11 | $3,384 |
| AstraZeneca | 22 | $485 |
| Otsuka America Pharmaceutical, Inc. | 6 | $361 |
| Bayer | 11 | $256 |
| Amgen | 8 | $192 |
| Fresenius USA Marketing, Inc. | 8 | $157 |
| Calliditas Therapeutics US Inc. | 7 | $145 |
| Nxstage Medical, Inc. | 3 | $141 |
| Cardinal Health 108 LLC | 2 | $124 |
| Vantive US Healthcare LLC | 1 | $120 |
| Ardelyx, Inc. | 5 | $108 |
| Travere Therapeutics, Inc. | 5 | $108 |
| Novo Nordisk | 2 | $46 |
| OPKO Pharmaceuticals, LLC | 3 | $43 |
| Aurinia Pharma U.S., Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Mallinckrodt Enterprises LLC | 1 | $32 |
| Ascendis Pharma Endocrinology Inc | 1 | $30 |
| Novartis | 1 | $23 |
| GSK | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$14,079
- AURYXIA$7,784
- Renal - PD$3,240
- JYNARQUE$191
How this compares
$28,910 in reported general payments places this provider in the 95th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 11 | $222,640 |
| FarxigaDapagliflozin Propanediol | 139 | $142,589 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $36,552 |
| ProcritEpoetin Alfa | 26 | $22,625 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $17,497 |
| JardianceEmpagliflozin | 20 | $17,337 |
| Cinacalcet Hcl | 16 | $13,052 |
| AuryxiaFerric Citrate | 18 | $12,251 |
| Nifedipine ErNifedipine | 214 | $7,239 |
| Sevelamer Carbonate | 37 | $4,277 |
| Furosemide | 830 | $4,234 |
| Chlorthalidone | 359 | $3,047 |
| Carvedilol | 193 | $1,519 |
| Spironolactone | 188 | $1,456 |
| Potassium Chloride | 111 | $1,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $361 | $222,64011 claims |
| AstraZenecaFarxiga, Lokelma | $485 | $160,086155 claims |
| Akebia Therapeutics IncAuryxia | $8,393 | $12,25118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Natchez
- Mohit AhujaFlowood$427K
- Brian RifkinHattiesburg$23K
- Otis GowdyMeridian$12K
- Richard MillerBrookhaven$10K
- Thomas WooldridgeTupelo$8K
- Steven WagnerFlowood$6K
- John Martin LeeTupelo$6K
- Francis PhillippiFlowood$6K
- Son LamOxford$6K
- Morris HamiltonTupelo$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.